Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.8052W HIGH $17.63
Volume
11.01 M
Value Traded
111.74 M
Short % Float
7.53%
Days to Cover
1.0
-0.29%Week
0%1 Month
+0.89%3 Month
+46.46%6 Month
-65.71%5 Year
-60.27%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
448.68 M
EPS (TTM)
-4.85
P/E Ratio
-
Ent. Value
-61.62 M
Total Shares
44.21 M
Float Shares
42.71 M
Insiders
6.26%
Institutions
116.32%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
ITOS Catalyst Timeline
Dated clinical, regulatory and corporate events for iTeos Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How ITOS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | EOS-984 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| inupadenant Small moleculeNCT05403385 | Metastatic NSCLC - Non-Small Cell Lung Cancer | Phase 2 | ACTIVE NOT_RECRUITING | 36 | Oct 1, 2025 | ||||||
| EOS301984 Small moleculeNCT06547957 | Advanced Solid Tumors | Phase 1 | ACTIVE NOT_RECRUITING | 55 | Dec 1, 2025 | ||||||
| inupadenant Small moleculeCompletedNCT05117177 | Solid Tumor, Adult | Phase 1 | COMPLETED | 57 | May 9, 2024 | ||||||
| EOS100850 Small moleculeCompletedNCT03873883 | Solid Tumor, Adult | Phase 1 | COMPLETED | 119 | May 28, 2024 | ||||||
| EOS884448 Small moleculeCompletedNCT04335253 | Advanced Cancer | Phase 1 | COMPLETED | 40 | Apr 7, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every ITOS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| belrestotug | non-small cell lung cancer | Phase 2 | 2025-05-13 | did not meet established criteria for clinically meaningful improvements in progression free survivalRead More | iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer PatientsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Detheux MichelChief Executive Officer | Option | 26,400 153,903 held | $4.30 | 06/10/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in ITOS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 6.3 % (950 %) | 106.57 M | 10.69 M | 564.48% ( 9.08 M) |
Ownership Trends
ITOS Short Interest
Shares sold short, counted twice a month.
7.53%
Short % of Float
of tradable shares sold short
896.8K
Shares Sold Short
-56.5% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
2.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ITOS ranks across every disease it competes in
Competitive Position is a premium feature
See how ITOS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialITOS News
About iTeos Therapeutics, Inc.
Founded24-07-2020
BIOPHARMAWATCH ELITE PLUS
Trade the next ITOS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime